

AMENDMENTS TO THE SPECIFICATION

Please replace the paragraph at page 1, line 4 (published as paragraph [0002]) as follows:

The present invention is directed to the use of ecteinascidin 743 for cancer therapy, in particular to the use of ecteinascidin 743 in combination with another active drug, doxorubicin (also referred to below as Doxo or doxo), for the treatment of cancer.